Beijing's Novogene Closes $75 Million B Round for Genomic Sequencing

01:17 EST 2 Dec 2016 | ChinaBio Today

Novogene Technology of Beijing closed a $75 million Series B round that was funded by China investors. Novogene, which has one of the largest sequencing capacities in the world, offers next-generation sequencing and bioinformatics services to biopharmas and hospitals. One year ago, Novogene formed a partnership with Illumina to develop clinical oncology diagnostics. Founded in 2011 by Dr. Ruiquiang Li, Novogene has nearly 1,000 employees in locations around the world. More details....

Stock Symbol: (NSDQ: ILMN)

Share this with colleagues:  

Original Article: Beijing's Novogene Closes $75 Million B Round for Genomic Sequencing


More From BioPortfolio on "Beijing's Novogene Closes $75 Million B Round for Genomic Sequencing"

Quick Search

Relevant Topics

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...